AstraZeneca to Invest $1B for the Transformation of Healthcare in China

 AstraZeneca to Invest $1B for the Transformation of Healthcare in China

AstraZeneca to Invest $1B for the Transformation of Healthcare in China

Shots:

  • AstraZeneca takes three large-scale initiatives which include the formation of new Global R&D Centre and an AI Innovation Centre, both in Shanghai and collaborate with CICC to jointly formed the Healthcare Industrial Fund for the transformation of healthcare in China
  • Initially, AstraZeneca funded $1B to the Health Care Fund supporting the domestic companies, the R&D Centre to focus on the disease prevalent in China and AI innovation Centre is to utilize digital technology in R&D, manufacturing, operations and commercialization to accelerate the delivery of therapies in China and across the globe
  • AstraZeneca signed MoU with the Shanghai Jing’an District People’s Government at the CIIE for the creation of R&D and AI Centres and a separate agreement with CICC for the joint investment fund. Additionally, AstraZeneca signed a license agreement with Sun Pharma for novel ready-to-use (RTU) infusion oncology therapies in China

Click here to­ read full press release/ article | Ref: AstraZeneca | Image: DW.com

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post